Inside food production plants, veterinary clinics, and farms, every hour matters. Pathogens threaten safety, quality, and profitability, yet traditional PCR diagnostics still live in centralized laboratories with turnaround times exceeding 24 hours and more. Bioaccure was built to close this operational gap. 

As the founder highlights, “The inspiration … came directly from our target customers,” and it quickly became clear that the food and animal systems industries needed fast, precise answers on-site. “Clients from the agri-food industry began asking whether [we] had similar diagnostic solutions … before visible symptoms appear.” Recognizing this urgent demand, Bioaccure set out to make PCR truly mobile. 

PCR.smart — Lab-Grade Results Wherever They Are Needed 

PCR.smart, Bioaccure’s flagship platform, brings laboratory-quality real-time PCR diagnostics directly to the point of action. It combines DNA extraction, amplification, detection, and interpretation into a single compact device that can operate without specialized laboratory infrastructure. Samples are processed and interpreted on-site in less than 90 minutes, a transformational improvement over traditional workflows, and the system includes a built-in DNA isolation slot to eliminate external sample preparation steps. Its heating-cooling performance, reaching heating 20°C per second, ranks among the fastest globally and contributes to both its speed and accuracy in field conditions. 

“Everything is designed for the specific application environment,” the founder emphasizes. “Our device delivers comparable accuracy [to top-tier lab systems] … and is significantly faster.” PCR diagnostics have never been this powerful, simple, and field-ready at the same time. 

Value Delivered Where It Matters Most 

The commercial strategy focuses on sectors where contamination, disease detection, and operational risk directly impact productivity and profitability. In food safety, internal qPCR screening allows production managers to detect issues earlier, prevent spoilage, and avoid costly recalls before products move downstream. In veterinary care, real-time molecular insights help clinicians select the appropriate treatment more quickly, shortening recovery time, improving welfare, and reducing the misuse of antibiotics. And in crop and plant health, early pathogen identification enables farmers to act before symptoms appear, lowering input costs while protecting yield and quality. 

Across all three areas, PCR.smart empowers operators to act immediately to protect value rather than waiting for delayed external lab results that may only confirm damage once it is too late. 

Diagnostics That Enable Faster, Smarter Decisions

PCR.smart operates directly in the environments where problems arise, delivering lab-quality results at the point of need. This allows producers and veterinarians to make better-informed decisions within hours rather than days. As the founder notes, “Our technology addresses issues such as antimicrobial resistance (AMR), food loss and waste, and animal health from field to table.”

Today, BioAccure’s business model is centred on providing robust devices and ready-to-use test panels that fit seamlessly into everyday workflows. In the future, aggregated testing data may create opportunities for more advanced analytics and decision support, but for now the focus remains on reliable, easy-to-use diagnostics that immediately reduce risk and operational uncertainty.

Commercialization with Strong Technical Validation 

Bioaccure is preparing its first production batch of devices for sale and deployment in Q1–Q2 2026, while simultaneously expanding its pathogen test panels across animal health, food contaminants, and plant diseases. This progress is reinforced by the company’s close relationship with Carlson Investments SE, which has played a key role in enabling Bioaccure to launch and scale the technology’s development, providing a stable foundation for commercialization. 

Why Investors Should Watch Bioaccure 

Bioaccure’s value proposition drives real operational urgency. When detection is delayed, organizations face revenue loss, recalls, disease spread, and regulatory consequences. PCR.smart removes this delay with validated technology that brings qPCR to the point of action. By enabling faster decisions when they matter most, Bioaccure helps safeguard both business continuity and brand trust. 

Built to Lead a New Era of Biosurveillance 

The startup is operating at the intersection of major global shifts, decentralized testing, stricter regulatory expectations for food traceability, rising AMR threats, and climate-linked pathogen volatility. The team is designing for long-term category leadership: “Our goal is to be fully prepared for commercialization … [and] focus on further technology development, test expansion, and global distribution.” 

What is emerging is not a device company but a diagnostics platform combining rugged next-generation hardware, high-value consumables, and – in the future – predictive analytics; a rare asset with scalable growth potential across multiple resilient industries.